188 related articles for article (PubMed ID: 36824294)
21. Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.
Kulkarni HS; Cherikh WS; Chambers DC; Garcia VC; Hachem RR; Kreisel D; Puri V; Kozower BD; Byers DE; Witt CA; Alexander-Brett J; Aguilar PR; Tague LK; Furuya Y; Patterson GA; Trulock EP; Yusen RD
J Heart Lung Transplant; 2019 Jan; 38(1):5-16. PubMed ID: 30391193
[TBL] [Abstract][Full Text] [Related]
22. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation.
Glanville AR; Aboyoun C; Klepetko W; Reichenspurner H; Treede H; Verschuuren EA; Boehler A; Benden C; Hopkins P; Corris PA;
J Heart Lung Transplant; 2015 Jan; 34(1):16-25. PubMed ID: 25049068
[TBL] [Abstract][Full Text] [Related]
23. The potential of biomarkers of fibrosis in chronic lung allograft dysfunction.
van der Ploeg EA; Melgert BN; Burgess JK; Gan CT
Transplant Rev (Orlando); 2021 Jul; 35(3):100626. PubMed ID: 33992914
[TBL] [Abstract][Full Text] [Related]
24. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.
Benden C; Haughton M; Leonard S; Huber LC
J Heart Lung Transplant; 2017 Sep; 36(9):921-933. PubMed ID: 28662986
[TBL] [Abstract][Full Text] [Related]
25. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
Su L; Tam N; Deng R; Chen P; Li H; Wu L
Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
[TBL] [Abstract][Full Text] [Related]
26. Incidence and impact of chronic lung allograft dysfunction after lung transplantation - single-center 14-year experience.
Nykänen A; Raivio P; Peräkylä L; Stark C; Huuskonen A; Lemström K; Halme M; Hämmäinen P
Scand Cardiovasc J; 2020 Jun; 54(3):192-199. PubMed ID: 32148103
[No Abstract] [Full Text] [Related]
27. Quantitative chest CT for subtyping chronic lung allograft dysfunction and its association with survival.
Horie M; Salazar P; Saito T; Binnie M; Brock K; Yasufuku K; Azad S; Keshavjee S; Martinu T; Paul N
Clin Transplant; 2018 May; 32(5):e13233. PubMed ID: 29637624
[TBL] [Abstract][Full Text] [Related]
28. Connective Tissue Growth Factor Is Overexpressed in Explant Lung Tissue and Broncho-Alveolar Lavage in Transplant-Related Pulmonary Fibrosis.
Vanstapel A; Goldschmeding R; Broekhuizen R; Nguyen T; Sacreas A; Kaes J; Heigl T; Verleden SE; De Zutter A; Verleden G; Weynand B; Verbeken E; Ceulemans LJ; Van Raemdonck DE; Neyrinck AP; Schoemans HM; Vanaudenaerde BM; Vos R
Front Immunol; 2021; 12():661761. PubMed ID: 34122421
[TBL] [Abstract][Full Text] [Related]
29. Time-dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (BOS).
Sato M; Ohmori-Matsuda K; Saito T; Matsuda Y; Hwang DM; Waddell TK; Singer LG; Keshavjee S
J Heart Lung Transplant; 2013 May; 32(5):484-91. PubMed ID: 23433813
[TBL] [Abstract][Full Text] [Related]
30. Chronic lung allograft dysfunction phenotype and prognosis by machine learning CT analysis.
McInnis MC; Ma J; Karur GR; Houbois C; Levy L; Havlin J; Fuchs E; Tikkanen J; Chow CW; Huszti E; Martinu T
Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 34949699
[TBL] [Abstract][Full Text] [Related]
31. Peripheral CD4+ CD25+ Treg cell expansion in lung transplant recipients is not affected by calcineurin inhibitors.
Meloni F; Morosini M; Solari N; Bini F; Vitulo P; Arbustini E; Pellegrini C; Fietta AM
Int Immunopharmacol; 2006 Dec; 6(13-14):2002-10. PubMed ID: 17161354
[TBL] [Abstract][Full Text] [Related]
32. Ventilatory capacity in CLAD is driven by dysfunctional airway structure.
Kerckhof P; Ambrocio GPL; Beeckmans H; Kaes J; Geudens V; Bos S; Willems L; Vermaut A; Vermant M; Goos T; De Fays C; Aversa L; Mohamady Y; Vanstapel A; Orlitová M; Van Slambrouck J; Jin X; Varghese V; Josipovic I; Boone MN; Dupont LJ; Weynand B; Dubbeldam A; Van Raemdonck DE; Ceulemans LJ; Gayan-Ramirez G; De Sadeleer LJ; McDonough JE; Vanaudenaerde BM; Vos R
EBioMedicine; 2024 Mar; 101():105030. PubMed ID: 38394744
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapy of chronic lung allograft dysfunction post lung transplantation.
Evans RA; Walter KS; Lobo LJ; Coakley R; Doligalski CT
Clin Transplant; 2022 Aug; 36(8):e14770. PubMed ID: 35801376
[TBL] [Abstract][Full Text] [Related]
34. Transition from BOS to RAS impairs prognosis after lung transplantation-CLAD subtype analysis by CT volumetry.
Peräkylä L; Nykänen A; Piilonen A; Kesävuori R; Halme M; Raivio P
PLoS One; 2022; 17(10):e0275563. PubMed ID: 36223371
[TBL] [Abstract][Full Text] [Related]
35. Impact of chronic lung allograft dysfunction, especially restrictive allograft syndrome, on the survival after living-donor lobar lung transplantation compared with cadaveric lung transplantation in adults: a single-center experience.
Sugimoto S; Yamamoto H; Kurosaki T; Otani S; Okazaki M; Yamane M; Toyooka S; Oto T
Surg Today; 2019 Aug; 49(8):686-693. PubMed ID: 30790054
[TBL] [Abstract][Full Text] [Related]
36. Chronic lung allograft dysfunction: evolving practice.
Vos R; Verleden SE; Verleden GM
Curr Opin Organ Transplant; 2015 Oct; 20(5):483-91. PubMed ID: 26262458
[TBL] [Abstract][Full Text] [Related]
37. Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
Transplant Proc; 2019 Jun; 51(5):1424-1427. PubMed ID: 31060742
[TBL] [Abstract][Full Text] [Related]
38. The role of biomechanical anatomical modeling via computed tomography for identification of restrictive allograft syndrome.
Horie M; Saito T; Moseley J; D'Errico L; Salazar P; Nakajima D; Brock K; Yasufuku K; Binnie M; Keshavjee S; Paul N
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658530
[TBL] [Abstract][Full Text] [Related]
39. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
40. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
